125 related articles for article (PubMed ID: 30318520)
1. Mutant p53 blocks SESN1/AMPK/PGC-1α/UCP2 axis increasing mitochondrial O
Cordani M; Butera G; Dando I; Torrens-Mas M; Butturini E; Pacchiana R; Oppici E; Cavallini C; Gasperini S; Tamassia N; Nadal-Serrano M; Coan M; Rossi D; Gaidano G; Caraglia M; Mariotto S; Spizzo R; Roca P; Oliver J; Scupoli MT; Donadelli M
Br J Cancer; 2018 Oct; 119(8):994-1008. PubMed ID: 30318520
[TBL] [Abstract][Full Text] [Related]
2. Targeting mutant p53-R248W reactivates WT p53 function and alters the onco-metabolic profile.
Brown K; Jenkins LMM; Crooks DR; Surman DR; Mazur SJ; Xu Y; Arimilli BS; Yang Y; Lane AN; Fan TW; Schrump DS; Linehan WM; Ripley RT; Appella E
Front Oncol; 2022; 12():1094210. PubMed ID: 36713582
[No Abstract] [Full Text] [Related]
3. Proteasome inhibition paradoxically degrades gain-of-function mutant p53 R273H in NSCLC and could have therapeutic implications.
Oduah EI; Sharfstein ST; Seetharamu N; Grossman SR; Litovchick L
Front Oncol; 2024; 14():1363543. PubMed ID: 38660140
[TBL] [Abstract][Full Text] [Related]
4. Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.
Redaelli S; Ceccon M; Zappa M; Sharma GG; Mastini C; Mauri M; Nigoghossian M; Massimino L; Cordani N; Farina F; Piazza R; Gambacorti-Passerini C; Mologni L
Cancer Res; 2018 Dec; 78(24):6866-6880. PubMed ID: 30322862
[TBL] [Abstract][Full Text] [Related]
5. How I treat infant leukemia.
Brown P; Pieters R; Biondi A
Blood; 2019 Jan; 133(3):205-214. PubMed ID: 30459160
[TBL] [Abstract][Full Text] [Related]
6. p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression.
Amelio I; Mancini M; Petrova V; Cairns RA; Vikhreva P; Nicolai S; Marini A; Antonov AA; Le Quesne J; Baena Acevedo JD; Dudek K; Sozzi G; Pastorino U; Knight RA; Mak TW; Melino G
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10869-E10878. PubMed ID: 30381462
[TBL] [Abstract][Full Text] [Related]
7. Restoring guardianship of the genome: Anticancer drug strategies to reverse oncogenic mutant p53 misfolding.
Babikir HA; Afjei R; Paulmurugan R; Massoud TF
Cancer Treat Rev; 2018 Dec; 71():19-31. PubMed ID: 30336366
[TBL] [Abstract][Full Text] [Related]
8. SirT3 regulates diabetogenic effects caused by arsenic: An implication for mitochondrial complex II modification.
Rezaei M; Keshtzar E; Khodayar MJ; Javadipour M
Toxicol Lett; 2019 Feb; 301():24-33. PubMed ID: 30385301
[TBL] [Abstract][Full Text] [Related]
9. Methods to Screen Compounds Against Mutant p53 Misfolding and Aggregation for Cancer Therapeutics.
Ferretti GDDS; da Costa DCF; L Silva J; Pereira Rangel L
Methods Mol Biol; 2019; 1873():265-277. PubMed ID: 30341616
[TBL] [Abstract][Full Text] [Related]
10. Awakening the "guardian of genome": reactivation of mutant p53.
Binayke A; Mishra S; Suman P; Das S; Chander H
Cancer Chemother Pharmacol; 2019 Jan; 83(1):1-15. PubMed ID: 30324219
[TBL] [Abstract][Full Text] [Related]
11. Raman micro-spectroscopy monitors acquired resistance to targeted cancer therapy at the cellular level.
Hammoud MK; Yosef HK; Lechtonen T; Aljakouch K; Schuler M; Alsaidi W; Daho I; Maghnouj A; Hahn S; El-Mashtoly SF; Gerwert K
Sci Rep; 2018 Oct; 8(1):15278. PubMed ID: 30323297
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value.
Hidalgo-Lόpez JE; Kanagal-Shamanna R; Quesada AE; Gong Z; Wang W; Hu S; Medeiros LJ; Bassett RL; d'Orcy E; Yin CC; Cortes J; Jabbour EJ; Kantarjian HM; Bueso-Ramos CE
Cancer; 2018 Oct; 124(19):3849-3855. PubMed ID: 30321462
[TBL] [Abstract][Full Text] [Related]
13. Sirtuin 3 silencing impairs mitochondrial biogenesis and metabolism in colon cancer cells.
Torrens-Mas M; Hernández-López R; Pons DG; Roca P; Oliver J; Sastre-Serra J
Am J Physiol Cell Physiol; 2019 Aug; 317(2):C398-C404. PubMed ID: 31188638
[TBL] [Abstract][Full Text] [Related]
14. Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer Cells.
Cordani M; Butera G; Pacchiana R; Masetto F; Mullappilly N; Riganti C; Donadelli M
Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111081
[TBL] [Abstract][Full Text] [Related]
15. PGC-1α in Disease: Recent Renal Insights into a Versatile Metabolic Regulator.
Chambers JM; Wingert RA
Cells; 2020 Oct; 9(10):. PubMed ID: 33022986
[TBL] [Abstract][Full Text] [Related]
16. Multifaceted mitochondria: moving mitochondrial science beyond function and dysfunction.
Monzel AS; Enríquez JA; Picard M
Nat Metab; 2023 Apr; 5(4):546-562. PubMed ID: 37100996
[TBL] [Abstract][Full Text] [Related]
17. Orientin alleviates ox-LDL-induced oxidative stress, inflammation and apoptosis in human vascular endothelial cells by regulating Sestrin 1 (SESN1)-mediated autophagy.
Gao F; Zhao Y; Zhang B; Xiao C; Sun Z; Gao Y; Dou X
J Mol Histol; 2024 Feb; 55(1):109-120. PubMed ID: 38165567
[TBL] [Abstract][Full Text] [Related]
18. Multifaceted roles of mitochondrial dysfunction in diseases: from powerhouses to saboteurs.
Prabhu SS; Nair AS; Nirmala SV
Arch Pharm Res; 2023 Oct; 46(9-10):723-743. PubMed ID: 37751031
[TBL] [Abstract][Full Text] [Related]
19. Targeting mutant p53 stabilization for cancer therapy.
Wang J; Liu W; Zhang L; Zhang J
Front Pharmacol; 2023; 14():1215995. PubMed ID: 37502209
[TBL] [Abstract][Full Text] [Related]
20. [EHHADH is a key gene in fatty acid metabolism pathways in hepatocellular carcinoma: a transcriptomic analysis].
Xie S; Li M; Jiang F; Yi Q; Yang W
Nan Fang Yi Ke Da Xue Xue Bao; 2023 May; 43(5):680-693. PubMed ID: 37313808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
